<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436655</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00011929</org_study_id>
    <nct_id>NCT02436655</nct_id>
  </id_info>
  <brief_title>Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Centre of Serbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Centre of Serbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left
      ventricular ejection fraction remains controversial. The investigators therefore try to
      compare clinical outcomes of elective aortic valve replacement to conventional treatment and
      watchful waiting strategy in a prospective randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic valve replacement (AVR) therapy is obvious choice in symptomatic severe aortic
      stenosis (AS) patients, because it improves symptoms, LV function and survival. Therefore,
      the accurate diagnosis of the disease, determination of its severity and precise evaluation
      of patients' clinical status is essential. However, the treatment decisions and indication
      for AVR in asymptomatic patients with severe AS and normal left ventricular ejection fraction
      (LV EF) are vague and the subject of ongoing debate. The most recent European and American
      guidelines have class I indication for AVR in asymptomatic severe AS patients with normal LV
      EF only in patients already scheduled for other cardiac surgery (for example by-pass
      surgery). In the case of symptom positive stress test American and European guideline
      differs, with European guidelines having class I indication and American guidelines only IIb
      indication. In all those cases of asymptomatic severe AS patients with normal LV EF the level
      of evidence is C, in other words there are no randomized trials. The consequence is that the
      decisions are made individually, patient by patient, and for this reason a patient with
      identical echocardiographic/clinical characteristics might be operated in USA but not in
      Europe (or any other part in the world), and vice-versa.

      With the experience that has accumulated so far, there are retrospective and observational
      data that elective AVR might lead to favorable outcome compared to late (after symptom onset)
      surgery. This may especially come to attention with the understanding that annual risk of
      sudden cardiac death in asymptomatic severe AS patients with normal LV EF might be very
      similar or even a bit higher than operative mortality in experienced cardiac surgery centers.

      Nevertheless, the majority of cardiologist worldwide are reluctant to send their asymptomatic
      patient with isolated severe AS and normal LV EF to AVR, and it will probably stay like that
      till randomized trials give us an answer whether elective AVR is beneficial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause death, Major Adverse Cardiac Event (MACE) including: ( Acute Myocardial Infarction - AMI, Stroke - CVI, unplanned hospitalization for Heart failure (HF) needing intravenous treatment</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>in-hospital and 30 days operative mortality in operated patients in both groups</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeat aortic valve surgery in operated patients in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding according to consensus report from the Bleeding Academic Research Consortium</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic complications based on clinical symptoms, signs and imaging studies</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeated major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>conventional drug treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elective aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>elective aortic valve surgery (replacement) within 4 weeks after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical aortic valve replacement</intervention_name>
    <description>open heart aortic valve replacement</description>
    <arm_group_label>elective aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women of any ethnic origin aged ≥18 years

          -  Written informed consent

          -  V max across the aortic valve &gt; 4m/s or Pmean ≥ 40mmHg and AVA ≤ 1cm2 or AVAi ≤
             0.6cm2/m2 at rest

          -  Without reported symptoms

          -  Society of Thoracic Surgeons (STS) score &lt; 8%

        Exclusion Criteria:

          -  Participation in another clinical trial within 30 days prior randomization

          -  Pregnant or nursing women

          -  Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study or to follow the protocol

          -  Positive stress-test defined as:

               1. Anginal chest pain during testing

               2. Syncope, dizziness during testing

               3. Decrease in systolic blood pressure during exercise ≥ 20mmHg

               4. Malignant arrhythmia during exercise testing (VT or VF)

          -  Left ventricular ejection fraction &lt; 50% at rest

          -  Very severe AS (defined as Vmax &gt; 5.5 m/s at rest)

          -  Significant disease of other valves (Mitral stenosis with Pmean &gt; 5mg, or any
             significant regurgitation ≥ 3+

          -  Recent AMI (&lt; 1 year)

          -  Need for additional by-pass surgery or for aortic root replacement (i.e Bentall) or
             ascending aorta in asymptomatic patients undergoing AVR

          -  Previous by-pass surgery

          -  Previous any heart valve surgery

          -  Impaired renal function, i.e. creatinine &gt;200 µmol/L or glomerular filtration rate &lt;
             30 mL/min/1.73 m2

          -  Significant pulmonary hypertension at rest (PASP &gt; 50mmHg)

          -  Uncontrolled hypertension at rest (systolic &gt;180 mmHg and diastolic &gt;100 mmHg)

          -  Significant co-morbidity with reduced life expectance (&lt; 3 years)

          -  Uncontrolled Diabetes Mellitus (HbA1C &gt; 9 %)

          -  Significant COPD (FEV1 &lt; 70% of predicted value)

          -  Permanent or paroxysmal atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marko Banovic, MD, PhD, FESC, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department, University Clinical Centre of Serbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetozar Putnik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Surgery Department, University Clinical Centre of Serbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivana M Živković, MD</last_name>
    <email>ivanazivkovic1985@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miodrag Jovanovic</last_name>
    <email>budimskivg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9320</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Penicka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy Van Camp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center &quot;Rebro&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Davor Milicic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hrvoje Gasparovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center ''Sestre milosrdnice''</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikola Pavlovic, MD</last_name>
      <phone>+385 1 3787 733</phone>
      <email>nikolap12@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Šime Manola, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikola Pavlovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Nemec, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radka Kockova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Radka Kockova, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiry Maly, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique de Haut Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecile Jore</last_name>
      <phone>+ 33 5 57 65 64 37</phone>
      <email>cecile.jore@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Louis Labrousse, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+353 91 524222</phone>
    </contact>
    <investigator>
      <last_name>Faisal Sharif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark daCosta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sigita.glaveckaite@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Sigita Glaveckaite, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <zip>40005</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wojciech Wojakowski, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marek Deja, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center 'Dedinje&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srdjaen Boskovic, MD</last_name>
      <email>boskovics@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Srdjan Boskovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Predrag Milojevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCSerbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Ristic</last_name>
      <phone>+381113663294</phone>
      <email>maraja18@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gordana Isakovic</last_name>
      <phone>+381113613653</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Clinical Center &quot;Bezanijska Kosa&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marija Zdravkovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasa Cvetinovic, MD</last_name>
      <email>ncvetinovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Goran Loncar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominguez-Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Dominguez-Rodriguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Carabello BA. Should severe aortic stenosis be operated on before symptom onset? Aortic valve replacement should be operated on before symptom onset. Circulation. 2012 Jul 3;126(1):112-7. doi: 10.1161/CIRCULATIONAHA.111.079350. Review.</citation>
    <PMID>22753532</PMID>
  </reference>
  <reference>
    <citation>Kang DH, Park SJ, Rim JH, Yun SC, Kim DH, Song JM, Choo SJ, Park SW, Song JK, Lee JW, Park PW. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 2010 Apr 6;121(13):1502-9. doi: 10.1161/CIRCULATIONAHA.109.909903. Epub 2010 Mar 22.</citation>
    <PMID>20308614</PMID>
  </reference>
  <reference>
    <citation>Malaisrie SC, McCarthy PM, McGee EC, Lee R, Rigolin VH, Davidson CJ, Beohar N, Lapin B, Subacius H, Bonow RO. Contemporary perioperative results of isolated aortic valve replacement for aortic stenosis. Ann Thorac Surg. 2010 Mar;89(3):751-6. doi: 10.1016/j.athoracsur.2009.11.024.</citation>
    <PMID>20172121</PMID>
  </reference>
  <reference>
    <citation>Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M; ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012 Oct;42(4):S1-44. doi: 10.1093/ejcts/ezs455. Epub 2012 Aug 25.</citation>
    <PMID>22922698</PMID>
  </reference>
  <reference>
    <citation>Banovic M, Iung B, Bartunek J, Asanin M, Beleslin B, Biocina B, Casselman F, da Costa M, Deja M, Gasparovic H, Kala P, Labrousse L, Loncar Z, Marinkovic J, Nedeljkovic I, Nedeljkovic M, Nemec P, Nikolic SD, Pencina M, Penicka M, Ristic A, Sharif F, Van Camp G, Vanderheyden M, Wojakowski W, Putnik S. Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. Am Heart J. 2016 Apr;174:147-53. doi: 10.1016/j.ahj.2016.02.001. Epub 2016 Feb 9.</citation>
    <PMID>26995381</PMID>
  </reference>
  <reference>
    <citation>Banovic M, Iung B, Bartunek J, Penicka M, Vanderheyden M, Casselman F, van Camp G, Nikolic S, Putnik S. The Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A protocol update. Am Heart J. 2018 Jan;195:153-154. doi: 10.1016/j.ahj.2017.10.005. Epub 2017 Oct 14.</citation>
    <PMID>29224644</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Centre of Serbia</investigator_affiliation>
    <investigator_full_name>Marko Banovic</investigator_full_name>
    <investigator_title>MD PhD, FESC, FACC, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>normal ejection fraction</keyword>
  <keyword>asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

